A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Papadimitriou, Christos A ^a   Papakostas, Pavlos ^b   Karina, Maria ^c   Malettou, Lia ^d   Dimopoulos, Meletios A ^a   Pentheroudakis, George ^e   Samantas, Epaminontas ^f   Bamias, Aristotelis ^a   Miliaras, Dimosthenis ^c   Basdanis, George ^c   Xiros, Nikolaos ^g   Klouvas, George ^h   Bafaloukos, Dimitrios ^h   Kafiri, Georgia ^b   Papaspirou, Irene ⁱ   Pectasides, Dimitrios ^g   Karanikiotis, Charisios ^j   Economopoulos, Theofanis ^g   Efstratiou, Ioannis ^k   Korantzis, Ippokratis ^c   Pisanidis, Nikolaos ^l   Makatsoris, Thomas ^m   Matsiakou, Fotini ^b   Aravantinos, Gerasimos ^f   Kalofonos, Haralabos P ^m   Fountzilas, George ^c   more..

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Ippokration Hospital Thessaloniki   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d Hellenic Cooperative Oncology Group   (Greece)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^f AGII ANARGIRI CANCER HOSPITAL   (Greece)

^g NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^h METROPOLITAN HOSPITAL   (Greece)

ⁱ ALEXANDRA HOSPITAL   (Greece)

^j 424 General Army Hospital   (Greece)

^k PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^l IKA Hospital   (Greece)

^m UNIVERSITY HOSPITAL OF PATRAS   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; COLON CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; EPIPHORA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; THROMBOCYTOPENIA; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; COLON TUMOR; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; GREECE; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; GREECE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79251553445     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-10     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43, 17237035.
2. Martenson JA, Willett CG, Sargent DJ, Mailliard JA, Donohue JH, Gunderson LL, Charles R, Thomas CR, Fisher B, Benson AB, Myerson R, Goldberg RM. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol 2004, 22:3277-3283. 10.1200/JCO.2004.01.029, 15249584.
3. Chau I, Cunningham D. Adjuvant therapy in colon cancer - what, when and how?. Annals of Oncology 2006, 17:1347-1359. 10.1093/annonc/mdl029, 16524974.
4. André T, Afchain P, Barrier A, Blanchard P, Larsen AK, Tournigand C, Louvet C, de Gramont A. Current Status of Adjuvant Therapy for Colon Cancer. Gastrointest Cancer Res 2007, 1:90-97. 2632821, 19262714.
5. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008, 134:1296-1310. 10.1053/j.gastro.2008.02.098, 2528832, 18471507.
6. O'Connell MJ. Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. J Clin Oncol 2009, 27:3082-3084.
7. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002, 8:641-61.
8. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003, 361:2235-2242. 10.1016/S0140-6736(03)13780-4, 12842380.
9. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993, 11:909-913.
10. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996, 14:709-715.
11. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou Y, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997, 15:251-260.
12. Kalofonos HP, Skarlos D, Bafaloukos D, Papakostas P, Bamias A, Janinis J, Timotheadou E, Kouvatseas G, Stavropoulos M, Economopulos T, Fountzilas G. A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma. Cancer Invest 2003, 21:855-862. 10.1081/CNV-120025088, 14735689.
13. Timotheadou E, Papakostas P, Tsavdaridis D, Basdanis G, Kalofonos H, Aravantinos G, Bafaloukos D, Fountzilas G. Irinotecan and oxaliplatin combination, as second-line treatment, in fluoropyrimidine-pretreated advanced colorectal cancer. A phase II study by the Hellenic Cooperative Oncology Group (HeCOG). Tumori 2005, 91:309-313.
14. Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413-1418. 10.1016/S0140-6736(98)02309-5, 9807987.
15. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000, 355:1041-1047. 10.1016/S0140-6736(00)02034-1, 10744089.
16. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 2000, 343:905-914. 10.1056/NEJM200009283431302, 11006366.
17. Kalofonos HP, Aravantinos G, Kosmidis P, Papakostas P, Economopoulos T, Dimopoulos M, Skarlos D, Bamias A, Pectasides D, Chalkidou S, Karina M, Koutras A, Samantas E, Bacoyiannis C, Samelis GF, Basdanis G, Kalfarentzos F, Fountzilas G. Irinotecan or oxaliplatin combined with leucovorin and 5-fuorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomised, phase II study. Ann Oncol 2005, 16:869-877. 10.1093/annonc/mdi193, 15855226.
18. Fountzilas G, Zisiadis A, Dafni U, Konstantaras C, Hatzitheoharis G, Papavramidis S, Bousoulegas A, Basdanis G, Giannoulis E, Dokmetzioglou J, Katsohis C, Nenopoulou E, Karvounis N, Briassoulis E, Aravantinos G, Kosmidis P, Skarlos D, Pavlidis N. Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Oncology 2000, 58:227-236. 10.1159/000012105, 10765125.
19. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, . Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators.
20. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007, 25:3456-3461. 10.1200/JCO.2007.11.2144, 17687149.
21. Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham C, Tabernero J, André T, Sobrero AF, Mini E, Greil R, Di Costanzo F, Collette L, Cisar L, Zhang X, Khayat D, Bokemeyer C, Roth AD, Cunningham D. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009, 27:3117-3125. 10.1200/JCO.2008.21.6663, 19451425.
22. Ychou M, Raoul JL, Douillard JY, Gourgou-Bourgade S, Bugat R, Mineur L, Viret F, Becouarn Y, Bouché O, Gamelin E, Ducreux M, Conroy T, Seitz JF, Bedenne L, Kramar A. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009, 20:674-680. 10.1093/annonc/mdn680, 19179549.
23. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, et al. Gruppo Oncologico Dell'Italia Meridionale Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell' Italia Meridionale. J Clin Oncol 2005, 23:4866-4875. 10.1200/JCO.2005.07.113, 15939922, Gruppo Oncologico Dell'Italia Meridionale.
24. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004, 22:229-237. 10.1200/JCO.2004.05.113, 14657227.
25. Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H, Proutski V, Swanton C, Tomlinson I, Delorenzi M, Fiocca R, Van Cutsem E, Roth A. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 2010, 15:390-404. 10.1634/theoncologist.2009-0233, 20350999.
26. Kostopoulos I, Karavasilis V, Karina M, Bobos M, Xiros N, Pentheroudakis G, Kafiri G, Papakostas P, Vrettou E, Fountzilas G. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. BMC Cancer 2009, 9:339. 10.1186/1471-2407-9-339, 2759966, 19775480.
27. Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009, 27:1814-1821. 10.1200/JCO.2008.18.2071, 2668707, 19273709.